Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Charles River Laboratories (NYSE: CRL) and Insightec have announced a five-year strategic collaboration to advance drug discovery and preclinical development in neuroscience using focused ultrasound (FUS) technology. The partnership aims to provide Charles River's clients access to a comprehensive global service and technology platform for FUS applications.
Insightec's low-frequency ultrasound platform non-invasively disrupts the blood-brain barrier, enabling targeted drug delivery to brain areas. This technology has shown positive clinical evidence in various neurological diseases, including Parkinson's, Alzheimer's, and oncology indications. The collaboration is designed to meet the increasing demand for advancing therapeutic development and delivery of genetic medicines, biologics, and immunotherapies in multiple Good Laboratory Practice (GLP) preclinical models in neuroscience.
Charles River Laboratories (NYSE: CRL) e Insightec hanno annunciato una collaborazione strategica di cinque anni per promuovere la scoperta di farmaci e lo sviluppo preclinico nella neuroscienza, utilizzando la tecnologia dell'ultrasuono focalizzato (FUS). L'obiettivo della partnership è fornire ai clienti di Charles River l'accesso a una piattaforma globale complessiva di servizi e tecnologia per le applicazioni FUS.
La piattaforma ad ultrasuoni a bassa frequenza di Insightec interrompe in modo non invasivo la barriera emato-encefalica, consentendo la somministrazione mirata di farmaci nelle aree cerebrali. Questa tecnologia ha dimostrato evidenze cliniche positive in varie malattie neurologiche, tra cui Parkinson, Alzheimer e indicazioni oncologiche. La collaborazione è progettata per soddisfare la crescente domanda di avanzamento nello sviluppo terapeutico e nella somministrazione di farmaci genetici, biologici e immunoterapie in diversi modelli preclinici di Buone Pratiche di Laboratorio (GLP) nella neuroscienza.
Charles River Laboratories (NYSE: CRL) e Insightec han anunciado una colaboración estratégica de cinco años para avanzar en el descubrimiento de fármacos y el desarrollo preclínico en neurociencia utilizando tecnología de ultrasonido focalizado (FUS). La asociación tiene como objetivo proporcionar a los clientes de Charles River acceso a una plataforma global integral de servicios y tecnología para aplicaciones de FUS.
La plataforma de ultrasonido de baja frecuencia de Insightec interrumpe de forma no invasiva la barrera hematoencefálica, permitiendo la entrega dirigida de medicamentos a áreas del cerebro. Esta tecnología ha mostrado evidencia clínica positiva en varias enfermedades neurológicas, incluyendo Parkinson, Alzheimer e indicaciones oncológicas. La colaboración está diseñada para satisfacer la creciente demanda de avanzar en el desarrollo terapéutico y la entrega de medicamentos genéticos, biológicos e inmunoterapias en múltiples modelos preclínicos de Buenas Prácticas de Laboratorio (GLP) en neurociencia.
찰스 리버 실험실(뉴욕증권거래소: CRL)과 인사이트텍(Insightec)은 집중 초음파(FUS) 기술을 이용하여 신경과학 분야의 약물 발견 및 전임상 개발을 진전시키기 위한 5년 전략적 협력을 발표했습니다. 이 파트너십의 목적은 찰스 리버의 고객에게 FUS 응용을 위한 포괄적인 글로벌 서비스 및 기술 플랫폼에 접근할 수 있도록 하는 것입니다.
인사이트텍의 저주파 초음파 플랫폼은 비침습적으로 혈액-뇌 장벽을 파괴하여 뇌 영역에 대한 표적 약물 전달을 가능하게 합니다. 이 기술은 파킨슨병, 알츠하이머병, 종양학적 적응증을 포함한 다양한 신경 질환에서 긍정적인 임상 증거를 보여주었습니다. 이 협력은 유전자 의약품, 생물 의약품 및 면역치료의 치료 개발 및 전달에 대한 수요 증가를 충족하기 위해 설계되었습니다. 여러 신경 과학 분야의 좋은 실험실 관행(GLP) 전임상 모델에서 이루어집니다.
Charles River Laboratories (NYSE: CRL) et Insightec ont annoncé une collaboration stratégique de cinq ans pour faire progresser la découverte de médicaments et le développement préclinique en neuroscience en utilisant la technologie des ultrasons focalisés (FUS). L'objectif de ce partenariat est d'offrir aux clients de Charles River l'accès à une plateforme mondiale complète de services et de technologies pour les applications FUS.
La plateforme d'ultrason à basse fréquence d'Insightec interrompt de manière non invasive la barrière hémato-encéphalique, permettant la livraison ciblée de médicaments dans les zones cérébrales. Cette technologie a montré des preuves cliniques positives dans diverses maladies neurologiques, y compris les maladies de Parkinson, d'Alzheimer et dans des indications oncologiques. La collaboration est conçue pour répondre à la demande croissante d'avancement du développement thérapeutique et de livraison de médicaments génétiques, biologiques et d'immunothérapies dans plusieurs modèles précliniques de Bonnes Pratiques de Laboratoire (BPL) en neurosciences.
Charles River Laboratories (NYSE: CRL) und Insightec haben eine fünfjährige strategische Zusammenarbeit angekündigt, um die Arzneimittelentdeckung und die präklinische Entwicklung in der Neurowissenschaft mithilfe von fokussierter Ultraschalltechnologie (FUS) voranzutreiben. Ziel der Partnerschaft ist es, Charles River-Kunden Zugang zu einer umfassenden globalen Service- und Technologieplattform für FUS-Anwendungen zu bieten.
Die Low-Frequency-Ultrasound-Plattform von Insightec durchbricht nicht-invasiv die Blut-Hirn-Schranke und ermöglicht die gezielte Abgabe von Arzneimitteln an Gehirnareale. Diese Technologie hat in verschiedenen neurologischen Erkrankungen wie Parkinson, Alzheimer und onkologischen Indikationen positive klinische Nachweise erbracht. Die Zusammenarbeit soll der steigenden Nachfrage nach der Vorantreibung von therapeutischer Entwicklung und der Abgabe von genetischen Medikamenten, Biologika und Immuntherapien in mehreren Modellen der Guten Laborpraxis (GLP) in der Neurowissenschaft gerecht werden.
- Strategic collaboration with Insightec to advance drug discovery and preclinical development in neuroscience
- Access to innovative focused ultrasound technology for targeted drug delivery to the brain
- Potential to enhance precision and effectiveness of therapeutic delivery strategies
- Expansion of service offerings to meet increasing demand in neuroscience research
- None.
This collaboration between Charles River and Insightec marks a significant advancement in neuroscience research. The integration of Insightec's low-frequency focused ultrasound (FUS) technology with Charles River's preclinical services could potentially accelerate drug discovery and development for neurological conditions.
The key advantage of this technology lies in its ability to non-invasively disrupt the blood-brain barrier, a major obstacle in CNS drug delivery. This could dramatically improve the efficacy of various therapeutic agents, including genetic medicines, biologics and immunotherapies, by enabling targeted delivery to specific brain areas.
While promising, it's important to note that this collaboration is still at the preclinical stage. The true clinical impact and potential market value will depend on successful translation of this technology into human trials and eventual FDA approval. Investors should monitor future clinical trial results and regulatory milestones closely.
This strategic collaboration could potentially strengthen Charles River's position in the preclinical CRO market, particularly in neuroscience research. By offering access to Insightec's innovative FUS technology, Charles River may attract more clients and increase its market share in this high-value segment.
For Insightec, this partnership provides an opportunity to expand the application of their technology beyond clinical settings into the lucrative drug discovery and development market. This diversification could lead to new revenue streams and enhance the company's valuation.
However, the five-year timeframe of this collaboration suggests that significant financial impact may not be immediate. Investors should consider this a long-term strategic move rather than a short-term revenue booster. The success of this venture will likely depend on the adoption rate among Charles River's clients and the outcomes of subsequent preclinical studies using this technology.
Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions
“Our collaboration with Insightec represents a significant step forward in advancing neuroscience research,” said Professor Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer at Charles River. “As we look toward the future of drug discovery, we recognize that technology will be a cornerstone of innovation. The integration of focused ultrasound technology into our preclinical services will enhance the precision and effectiveness of therapeutic delivery strategies, allowing us to refine our use of research models and support the discovery of novel medicines.”
Collaboration in Neuroscience
Designed to meet the increasing demand to quickly advance therapeutic development and delivery of genetic medicines, biologics, and immunotherapies in multiple Good Laboratory Practice (GLP) preclinical models in neuroscience, the collaboration provides powerful CNS drug delivery for multiple drug types. Insightec’s low-intensity focused ultrasound along with microbubble resonators noninvasively modulate the blood-brain barrier, allowing precise therapeutic delivery of a variety of drugs, including delivery to deep brain structures. Insightec’s technology has the potential to revolutionize central nervous system (CNS) delivery for genetic medicines, biologics, and immunotherapies across a variety of tough-to-treat CNS diseases, including ones associated with neurodegeneration, neurodevelopment, and neuro-oncology.
“This partnership will not only expand the application of our low-frequency focused ultrasound technology, but also accelerate the development of groundbreaking therapies for neurological conditions,” said Arjun Desai, M.D., Chief Strategic Innovation Officer of Insightec. “By combining our expertise, we aim to revolutionize the way next generation therapeutics are delivered and actuated in the brain, ultimately improving the lives of millions globally.”
About Insightec
Insightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of focused ultrasound. The company’s Exablate Neuro platform focuses sound waves, safely guided by MRI, to provide tremor treatment to patients with medication-refractory essential tremor and Parkinson's disease. Both clinical and pre-clinical research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. Insightec is headquartered in
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding expectations with respect to the efficacy, effectiveness and precision of drug products. of Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec and/or Charles River as of the date of the statement. All written or oral forward-looking statements attributable to Insightec and/or Charles River are qualified by this caution. Insightec and/or Charles River does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec’s and/or Charles River’s expectations.
“Exablate,” and “Exablate Neuro,” as well as the “Insightec” logo, whether standing alone or in connection with the word “Insightec,” are protected trademarks of Insightec.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904804676/en/
Insightec Media Contact:
G&S Business Communications for Insightec
Marjani Williams
mwilliams@gscommunications.com
(312) 648-6700, ext.2108
Charles River Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: Charles River Laboratories International, Inc.
FAQ
What is the purpose of the collaboration between Charles River Laboratories and Insightec?
How does Insightec's focused ultrasound technology work in drug delivery?
What neurological conditions has Insightec's technology shown positive clinical evidence for?
How long is the strategic collaboration between Charles River Laboratories (CRL) and Insightec?
